Total Funding
3
Total FundingPost-IPO Debt raised
Growth Score
pts
Heat Score
-43 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3252152
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization.
Acquired by 
Cipher Pharmaceuticals
- Daniel Bednarik: Director, Genomics & Bioinformatics; Head, Infectious Diseases ProgramPast Role: Precigen, Vice President, Molecular Engineering Unit (MEU) Operations
About the Company
Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has one marketed product, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid
conversion of recent onset atrial fibrillation to sinus rhythm in adults.
